| |
| |
| Exchange: |
Nasdaq National Market |
| Security
Type: |
Common |
| Shares
Out: |
104,690,000 |
| Market
Cap: |
110.01(B) |
| Last
Volume: |
507,716 |
Avg
Vol: |
759,306 |
| 52
Week Range: |
$692.45 - $1071.19 |
|
| Level
I Sector: |
Health Care |
| Level
II Sector: |
Drugs |
| Level
III Sector: |
Biotechnology |
|
Member Indexes:
|
| |
S&P COMPOSITE 1500 |
|
NASDAQ BIOTECHNOLOGY |
| |
NASDAQ COMPOSITE |
|
S&P SMALLCAP 600 |
| |
NASDAQ NNM COMPOSITE |
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : 150 |
| Guru Rank Value : 6.9 |
| Guru Occurances : 2 |
|
|
|
|
|
| |
|
Company Profile Regeneron Pharmaceuticals is a biotechnology company that discovers, invents, develops, manufactures, and commercializes medicines for serious diseases. Co.'s products include: EYLEA (aflibercept) Injection, which is used for the treatment of neovascular age-related macular degeneration, diabetic macular edema, macular edema following retinal vein occlusion, myopic choroidal neovascularization, diabetic retinopathy, and neovascular glaucoma; REGEN-COV, which is used for the treatment of COVID-19; and Kevzara (sarilumab) Solution for Subcutaneous Injection, which is used for the treatment of rheumatoid arthritis.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
0 |
0 |
| Total Buy Value |
$0 |
$0 |
$0 |
$0 |
| Total People Bought |
0 |
0 |
0 |
0 |
| Total Buy Transactions |
0 |
0 |
0 |
0 |
| Total Shares Sold |
192,108 |
259,662 |
311,759 |
469,743 |
| Total Sell Value |
$188,697,290 |
$251,749,241 |
$294,950,701 |
$405,465,351 |
| Total People Sold |
7 |
14 |
16 |
18 |
| Total Sell Transactions |
18 |
45 |
67 |
128 |
| End Date |
2024-03-28 |
2023-12-26 |
2023-06-27 |
2022-06-27 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Landry Robert E |
EVP Finance CFO |
• – – |
2020-04-02 |
4 |
D |
$492.05 |
$1,140,080 |
D/D |
(2,317) |
26,409 |
|
- |
|
| Landry Robert E |
EVP Finance CFO |
• – – |
2020-04-02 |
4 |
OE |
$272.70 |
$818,100 |
D/D |
3,000 |
28,726 |
|
- |
|
| Larosa Joseph J |
EVP General Counsel and Secret |
• – – |
2020-04-02 |
4 |
AS |
$484.58 |
$3,330,406 |
D/D |
(6,797) |
14,438 |
|
23% |
|
| Fenimore Christopher R. |
VP Controller |
• – – |
2020-04-01 |
4 |
AS |
$478.77 |
$586,096 |
D/D |
(1,200) |
13,097 |
|
32% |
|
| Fenimore Christopher R. |
VP Controller |
• – – |
2020-04-01 |
4 |
OE |
$30.63 |
$36,756 |
D/D |
1,200 |
14,297 |
|
- |
|
| Landry Robert E |
EVP Finance CFO |
• – – |
2020-04-01 |
4 |
D |
$488.20 |
$2,268,735 |
D/D |
(4,647) |
25,726 |
|
- |
|
| Landry Robert E |
EVP Finance CFO |
• – – |
2020-04-01 |
4 |
OE |
$272.70 |
$1,636,200 |
D/D |
6,000 |
26,888 |
|
- |
|
| Landry Robert E |
EVP Finance CFO |
• – – |
2020-04-01 |
4 |
AS |
$478.97 |
$292,811 |
D/D |
(600) |
24,373 |
|
32% |
|
| Larosa Joseph J |
EVP General Counsel and Secret |
• – – |
2020-04-01 |
4 |
D |
$488.22 |
$4,004,869 |
D/D |
(8,203) |
21,235 |
|
- |
|
| Larosa Joseph J |
EVP General Counsel and Secret |
• – – |
2020-04-01 |
4 |
OE |
$59.20 |
$888,000 |
D/D |
15,000 |
23,924 |
|
- |
|
| Ryan Arthur F |
Director |
– • – |
2020-04-01 |
4 |
AS |
$477.58 |
$48,385 |
D/D |
(100) |
28,943 |
|
32% |
|
| Ryan Arthur F |
Director |
– • – |
2020-03-30 |
4 |
AS |
$462.80 |
$46,669 |
D/D |
(100) |
29,043 |
|
37% |
|
| Yancopoulos George |
President and Chief Scientific |
• • – |
2020-03-10 |
4 |
AS |
$461.79 |
$55,428,041 |
D/D |
(117,815) |
517,799 |
|
39% |
|
| Yancopoulos George |
President and Chief Scientific |
• • – |
2020-03-09 |
4 |
D |
$476.42 |
$61,420,543 |
D/D |
(128,921) |
635,614 |
|
- |
|
| Yancopoulos George |
President and Chief Scientific |
• • – |
2020-03-09 |
4 |
OE |
$30.63 |
$7,557,524 |
D/D |
246,736 |
713,990 |
|
- |
|
| Sanofi-Aventis |
|
• • • |
2020-03-09 |
4 |
S |
$489.65 |
$63,123,153 |
D/D |
(128,914) |
20,421,899 |
|
-32% |
|
| Goldstein Joseph L |
Director |
– • – |
2020-03-09 |
4 |
AS |
$468.14 |
$951,684 |
D/D |
(2,000) |
9,643 |
|
32% |
|
| Goldstein Joseph L |
Director |
– • – |
2020-03-09 |
4 |
OE |
$33.42 |
$66,840 |
D/D |
2,000 |
11,643 |
|
- |
|
| Stahl Neil |
EVP Research and Development |
• – – |
2020-02-27 |
4 |
AS |
$435.93 |
$4,680,460 |
D/D |
(10,349) |
11,380 |
|
48% |
|
| Stahl Neil |
EVP Research and Development |
• – – |
2020-02-26 |
4 |
GD |
$0.00 |
$0 |
D/D |
750 |
20,979 |
|
- |
|
| Sing George L |
Director |
– • – |
2020-02-26 |
4 |
S |
$450.00 |
$1,086,800 |
I/I |
(2,400) |
9,000 |
|
-51% |
|
| Sing George L |
Director |
– • – |
2020-02-26 |
4 |
S |
$460.00 |
$1,150,000 |
D/D |
(2,500) |
115,415 |
|
-51% |
|
| Sing George L |
Director |
– • – |
2020-02-26 |
4 |
OE |
$33.42 |
$83,550 |
D/D |
2,500 |
117,915 |
|
- |
|
| Stahl Neil |
EVP Research and Development |
• – – |
2020-02-26 |
4 |
D |
$451.89 |
$6,620,640 |
D/D |
(14,651) |
21,729 |
|
- |
|
| Stahl Neil |
EVP Research and Development |
• – – |
2020-02-26 |
4 |
OE |
$52.03 |
$1,300,750 |
D/D |
25,000 |
36,380 |
|
- |
|
2430 Records found
|
|
Page 33 of 98 |
|
|
| |
Transaction Code Key: |
Ownership Code Key |
| |
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
| |
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
| |
OE |
- Options Exercised |
A |
- Acquired |
| |
IO |
- Initital Ownership |
D |
- Disposed |
| |
|
|
|
|
|
18.30 (1.71%) 
